Q-omics provides the consensus-scored CCN6 profile across patient tissues and cancer cell-line models. CCN6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCN6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CCN6 RNA expression shows 15,323 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where CCN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCN6 survival associations across molecular data types. CCN6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCN6 RNA expression–survival associations across cancer types. High CCN6 expression shows unfavorable associations in ACC, LIHC, STAD and DLBC, but favorable associations in SKCM and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CCN6 RNA expression.
This table summarizes CCN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCN6 shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in HNSC and LUSC. The KIRC box plot shows higher CCN6 RNA expression in normal versus tumor tissue (log2 FC = −0.848, t-test p < 0.001).
This table shows molecular features associated with CCN6 in patient tissues and cancer cell lines. In patient samples, CCN6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
